Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 3, 2008

PerkinElmer Acquires Arnel to Fortify Services for the Biofuels Industry

  • PerkinElmer has taken over Arnel to bolster its application-focused expertise in the biofuels and hydrocarbon-processing industries. PerkinElmer also reports that the acquisition is an important strategic initiative to expand its chromatography portfolio.

    Arnel focuses on custom-engineered solutions for gas chromatography applications in the petrochemical, food and beverage, and industrial hygiene markets. Over the past 18 years, Arnel served as PerkinElmer’s exclusive supplier of gas sampling valve solutions.

    “PerkinElmer has a deep understanding of our customers’ specific industry-related challenges, whether these customers are in the pharmaceutical, consumer, or food-quality industries,” notes Richard Begley, Ph.D., president, PerkinElmer Analytical Sciences. “Our acquisition of Arnel brings us greater expertise in the hydrocarbon-processing industry through differentiated technology in gas chromatography.

    “In addition, we believe that combining Arnel’s technologies with PerkinElmer’s chromatography capabilities will help our customers develop cleaner, petroleum-based products to help reduce their impact on the environment as well as assist in manufacturing more cost-effective petroleum products.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »